Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.37

+0.9%

Dec 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (15057)	1/2/2005 1:44:47 PM
From: Qualified Opinion	of 52153

Pfizer indicated that it will be facing patent expirations on $14 billion of annual sales over the next three years. Furthermore, Pfizer's Lipitor will face more competition from Merck's Zocor which loses patent protection in 2006 in the U.S. Pfizer has become a balancing act between new drugs gaining traction against blockbuster drugs going generic. In the near term. I'm waiting for the full effect of the drop in sales of Celebrex, Bextra and Neurontin to be factored into earnings estimates and the stock price.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next